Literature DB >> 22471260

Reconstruction of the trapeziometacarpal joint in inflammatory joint disease using interposition of autologous tendon or poly-L-D-lactic acid implants: a prospective clinical trial.

Raine P Tiihonen1, Eerik T Skyttä, Kalevi Kaarela, Mikko Ikävalko, Eero A Belt.   

Abstract

Interposition arthroplasty with bioreplaceable poly-L-D-lactic acid (PLDLA) implants has yielded promising results in reconstruction of rheumatoid hands. In this prospective clinical study we compared the PLDLA implant arthroplasty (n = 17) with that of tendon interposition (n = 12) for destruction of the trapeziometacarpal joint in arthritic patients. There was no significant difference between the two groups preoperatively. At one-year follow-up, the mean pain and function scores were 5 and 13 in the PLDLA group, and 19 and 43 in the tendon interposition group, respectively. At one-year follow-up the visual analogue scale (VAS) for function of the PLDLA group differed significantly from that of the tendon interposition group (p = 0.03). This difference was not found at three months postoperatively, and disappeared again at two-year follow-up. Otherwise, no significant difference was found between the groups in the pain or function scores, functional tests, or range of movement. Bioreplaceable interposition arthroplasty works at least as well as tendon interposition. The operation is easier.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471260     DOI: 10.3109/2000656X.2012.669202

Source DB:  PubMed          Journal:  J Plast Surg Hand Surg        ISSN: 2000-6764


  2 in total

1.  Short-Term Results after Total Trapeziectomy with a Poly-L/D-Lactide Spacer.

Authors:  Kjell Van Royen; Bart Kestens; Sven Van Laere; Jean Goubau; Chul Ki Goorens
Journal:  J Wrist Surg       Date:  2018-07-02

Review 2.  Textile cell-free scaffolds for in situ tissue engineering applications.

Authors:  Dilbar Aibibu; Martin Hild; Michael Wöltje; Chokri Cherif
Journal:  J Mater Sci Mater Med       Date:  2016-01-22       Impact factor: 3.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.